DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3205-473-478$20.00
DMD 32:473-478, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, B.
Right arrow Articles by Tang, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, B.
Right arrow Articles by Tang, C.
SHORT COMMUNICATION

CYTOCHROME P450 2C8 (CYP2C8)-MEDIATED HYDROXYLATION OF AN ENDOTHELIN ETA RECEPTOR ANTAGONIST IN HUMAN LIVER MICROSOMES

Bennett Ma, Raju Subramanian, Michael L. Schrag, A. David Rodrigues, and Cuyue Tang

Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania (B.M., R.S., M.L.S., C.T.); and Bristol-Myers Squibb, Princeton, New Jersey (A.D.R.)

In vitro studies were performed to identify the human cytochrome P450 enzyme(s) involved in the hydroxylation (isopropyl moiety) of a previously reported endothelin ETA receptor antagonist, compound A [(+)-(5S,6R,7R)-2-isopropylamino-7-{4-methoxy-2-[(2R)-3-methoxy-2-methylpropyl]}-5-(3,4-methylenedioxyphenyl)cyclopenteno(1,2-b) pyridine 6-carboxylic acid]. Several lines of evidence indicated that the reaction was mainly catalyzed by CYP2C8. Of the 10 recombinant cytochrome P450 isoforms tested, only CYP2C8 exhibited hydroxylase activity. In agreement, inhibitory antibodies selective for CYP2C8 attenuated (>95%) the hydroxylase activity in human liver microsomes, whereas antibodies and chemical inhibitors selective for other cytochrome P450 isoforms had a minor or no effect on the reaction. In addition, the formation of the hydroxy metabolite correlated well with CYP2C8-selective paclitaxel 6{alpha}-hydroxylation (r2 ~0.92; p < 0.0001) and amodiaquine N-de-ethylation (r2 ~0.91; p < 0.0001) in a bank of human liver microsomes (n = 15 organ donors). Finally, compound A hydroxylase activity conformed to Michaelis-Menten kinetics, and the Km (Michaelis constant) in human liver microsomes was similar to that of CYP2C8 (~10 µM). It is concluded that the hydroxylation of compound A is mainly catalyzed by CYP2C8, and thus the reaction can possibly serve as an alternative marker assay for CYP2C8 in human liver microsomes.


Address correspondence to: Bennett Ma, Department of Drug Metabolism, WP 75A-203, Merck Research Laboratories, West Point, PA 19486. E-mail: bennett_ma{at}merck.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
B. Ma, S. L. Polsky-Fisher, S. Vickers, D. Cui, and A. D. Rodrigues
Cytochrome P450 3A-Dependent Metabolism of a Potent and Selective {gamma}-Aminobutyric AcidA{alpha}2/3 Receptor Agonist in Vitro: Involvement of Cytochrome P450 3A5 Displaying Biphasic Kinetics
Drug Metab. Dispos., August 1, 2007; 35(8): 1301 - 1307.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.